Bryn Mawr Trust CO Neurocrine Biosciences Inc Transaction History
Bryn Mawr Trust CO
- $5.51 Billion
- Q2 2025
A detailed history of Bryn Mawr Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bryn Mawr Trust CO holds 88 shares of NBIX stock, worth $11,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88
Previous 127
30.71%
Holding current value
$11,000
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
648Shares Held
96.9MCall Options Held
800KPut Options Held
565K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.24 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$692 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$608 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$334 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...